MCL1 and lip and oral cavity carcinoma: Selective inhibitors like Obatoclax, which specifically overcome Mcl-1 mediated resistance, is already in phase 2 clinical trials [33] and may have important therapeutic implications, when used in combination with radiotherapy in treatment of oral cancer patients.